Highlights Rigel Pharmaceuticals, Inc.

Equities

RIGL

US7665596034

Market Closed - Nasdaq Other stock markets 21:00:00 10/05/2024 BST			5-day change	1st Jan Change
0.9844 ^USD	-3.49%		-17.97%	-32.11%

05-07	Transcript : Rigel Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024
05-07	Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Posts Q1 Revenue $29.5M, vs. Street Est of $31.5M	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Posts Q1 Revenue $29.5M, vs. Street Est of $31.5M	05-07	MT
Rigel Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Rigel Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-05	CI
Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Posts Q4 Revenue $35.8M, vs. Street Est of $33.4M	03-05	MT
Rigel Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-05	CI
Rigel Pharmaceuticals Seeks Acquisitions	01-11	CI
Rigel Pharmaceuticals Enters Collaboration to Study Possible Treatment for Brain Tumors; Shares Rise	01-04	MT
Rigel Pharmaceuticals, Inc. Announces Collaboration with Connect to Conduct a Phase 2 Trial of Olutasidenib in Glioma	01-04	CI
Rigel Pharmaceuticals, MD Anderson Partner for Research on New Rezlidhia Indications	12-08	MT
Rigel Pharmaceuticals, Inc. and The University of Texas MD Anderson Cancer Center Announce Strategic Alliance to Advance REZLIDHIA®? (Olutasidenib) in AML and Other Cancers	12-08	CI
Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Posts Q3 Revenue $28.1M, vs. Street Est of $27.2M	11-07	MT
Rigel Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
Rigel Pharmaceuticals, Inc. Announces Poster Presentations At the 65Th American Society of Hematology Annual Meeting and Exposition	11-02	CI
Rigel Pharmaceuticals, Inc. Announces Presentation of Data from the Focus Phase 3 Clinical Trial of Fostamatinib in Hospitalized COVID-19 Patients and Provides Update on ACTIV-4 Host Tissue Trial	11/10/23	CI
Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Reports Q2 Revenue $26.9M, vs. Street Est of $25.7M	01/08/23	MT
Rigel Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	01/08/23	CI
Rigel Pharmaceuticals, Inc. Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML	07/06/23	CI
Rigel Pharmaceuticals, Inc. Announces Second -2-2-Appointment of Olutasidenib as Therapeutics	06/06/23	CI
Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Posts Q1 Revenue $26.1M, vs. Street Est of $24.1M	02/05/23	MT
Rigel Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	02/05/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Rigel Pharmaceuticals, Inc.

Equities

RIGL

US7665596034

Highlights

Filters